JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 17 No. 12 1073-1076
© 1976 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dunnick, J. K.
Right arrow Articles by Kriss, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunnick, J. K.
Right arrow Articles by Kriss, J. P.

Vesicle Interactions with Antibody and Peptide Hormone: Role of Vesicle Composition

June K. Dunnick*, Rodney S. Badger, Yosuke Takeda{dagger} and Joseph P. Kriss

Stanford University Medical Center, Stanford, California

Correspondence: For reprints contact: Joseph P. Kriss. Div. of Nuclear Medicine, Dept. of Radiology, Stanford University Medical Center, Stanford, CA 94305.

ABSTRACT

Artificial lipid vesicles (artificial membranes) were shown to bind human 125I-antithyroglobulin (anti-Tg) and human 125I-thyrotropin. Vesicles made with gangliosides bound more antibody and hormone than vesicles lacking them. These gangliosides contained a variety of carbohydrates including glucose, galactose, N-acetyl-galactosamine, and sialic acid. The in vivo stability of antibody-vesicle complexes was a function of vesicle composition: vesicles were most stable when formed from phosphatidylcholine, cholesterol, and gangliosides. Anti-Tg-vesicle complexes bind to thyroglobulin, indicating that at least some of the antibody associated with the vesicle still retains ability to bind to its specific antigen. The addition of a specific antibody or hormone to artificial lipid vesicles may serve as a mechanism to confer specificity to the vesicle in vivo.

FOOTNOTES

* Present address: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20014.

{dagger} Present address: Central Clinical Radioisotope Div., Kyoto University, Kyoto, Japan.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1976 by the Society of Nuclear Medicine.